Skip to content

The Blued+ Combination HIV Prevention Pilot Study in China

Integrating a Combination HIV Prevention Intervention Into a Widely-Used Geosocial App for Chinese MSM: Pilot Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06647173
Acronym
Blued+
Enrollment
423
Registered
2024-10-17
Start date
2022-07-15
Completion date
2024-02-28
Last updated
2025-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-Exposure Prophylaxis

Keywords

HIV Prevention, HIV Testing, Condom use, MSM, Dating Mobile Application

Brief summary

The proposed research includes a longitudinal pilot study to assess the feasibility and acceptability of Blued+. This combination HIV prevention intervention will integrate a combination package of HIV prevention services into Blued, a gay dating App, for men who have sex with men (MSM) in China. Despite high HIV incidence among MSM, HIV prevention interventions such as pre-exposure prophylaxis (PrEP) use remains low in China. If the HIV prevention intervention services provided through the Blued+ App prove feasible and acceptable, the pilot test will facilitate the design of a larger study of intervention efficacy. The study population will be self-reported HIV-negative Blued users who are 18 years of age or greater, were assigned a male sex at birth, report having anal sex with a man in the last 6 months, eligible for PrEP according to China's consensus statement, and reside in metropolitan Beijing or Chengdu, China.

Detailed description

The pilot study will be an interrupted time series cohort of 400 MSM. In two cities, a three-month baseline standard of care (SOC) period with measurement at 0 and 3 months will be followed by a 12-month intervention period with the measurement at 6, 9, 12, and 15 months. During the intervention, enrolled study participants will take surveys every 3 months, as well as have free access to the enhanced version of the Blued App, Blued+, which additionally provides HIV prevention intervention services such as HIV health messages, PrEP drugs, at-home HIV self-testing kits, condoms, and lubricants for no costs. Participants interested in PrEP will be required to have additional PrEP initiation physical exam clinical visits, follow-up clinical visits, and dry blood spot collection lab visits for blood PrEP level measurements. The total study period is 15 months (3 months control run-in period and 12 months intervention). Online surveys are provided over the study period, 2 for the enrollment and basement, and 4 follow-ups for every 3 months of the intervention; physical exam visits are required for participants who chose to initiate and refill PrEP; 1 dry blood spot collection visit is provided for participants who chose to measure blood PrEP level. The participants will be recruited online through the Blued App.

Interventions

BEHAVIORALBlued+ Service Platform

During the intervention period, participants received the enhanced version of the Blued app. The free HIV prevention services were integrated into the Blued app: health messaging, in-home HIV testing, linkage to care for those testing HIV positive, condoms, lubricants, in-app screening, and provision to PrEP.

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH
BlueD China
CollaboratorUNKNOWN
Emory University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Registered Blued app user * ≥18 years of age * Male sex at birth * Self-report anal sex with a man in the last 6 months * HIV-negative or unknown HIV status * Behaviorally eligible for PrEP per published China guidance * Able to complete study instruments in Mandarin Chinese * Resident of the metropolitan area of Beijing or Chengdu, China * Eligible for PrEP based on China's consensus statement * Additional Inclusion criteria apply for PrEP

Exclusion criteria

* Not a registered Blued app user * \<18 years of age * Not male sex at birth * Does not report anal sex with a man in the last 6 months * Has previously tested positive for HIV * Not eligible for PrEP per published China guidance * Unable to complete study instruments in Mandarin Chinese * Not a resident of the metropolitan area of Beijing or Chengdu, China * Currently enrolled in another HIV prevention study * Evidence of fraudulent participation, such as a duplicate IP address, multiple screening attempts, duplicate emails, etc. * Additional Inclusion criteria apply for PrEP

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of Blued+ in China12 months after intervention initiation, 15 months after first study interactionThe intervention will be determined to be feasible if a minimum proportion of participants receive services for home HIV testing (benchmark ≥30%) and PrEP initiation (benchmark ≥20%) through Blued+
System Usability Scale (SUS)12 months after intervention initiation, 15 months after first study interactionAcceptability of Blued+ in China will be measured using the System Usability Scale (SUS). The SUS is a widely used scale that evaluates the usability of products and systems through a 10-item question set. The total range of a score on this scale is 0 to 100. This scale does not have any sub-scales. Higher scores on this scale represent higher levels of intervention usability, with 100 being the highest usability and 0 being the lowest usability. Information on this scale and how to calculate values is found in: Bangor, Aaron, Philip T. Kortum, and James T. Miller. An empirical evaluation of the system usability scale. Intl. Journal of Human-Computer Interaction 24.6 (2008): 574-594. The intervention will be considered acceptable if it reaches a total SUS rating score of ≥ 71/100, which has been interpreted as being 'good' usability.

Countries

China

Participant flow

Participants by arm

ArmCount
Blued App
A three-month run-in period with the standard of care followed by the Blued+ intervention with participants for 12 months. Blued+ Service Platform: During the intervention period, participants received the enhanced version of the Blued app. The free HIV prevention services were integrated into the Blued app: health messaging, in-home HIV testing, linkage to care for those testing HIV positive, condoms, lubricants, in-app screening, and provision to PrEP.
423
Total423

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up24

Baseline characteristics

CharacteristicBlued App
Age, Continuous30 years
STANDARD_DEVIATION 7.4
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
423 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
0 Participants
Region of Enrollment
China
423 participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
423 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 423
other
Total, other adverse events
0 / 423
serious
Total, serious adverse events
0 / 423

Outcome results

Primary

Feasibility of Blued+ in China

The intervention will be determined to be feasible if a minimum proportion of participants receive services for home HIV testing (benchmark ≥30%) and PrEP initiation (benchmark ≥20%) through Blued+

Time frame: 12 months after intervention initiation, 15 months after first study interaction

Population: Participants retained at endline

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Blued AppFeasibility of Blued+ in ChinaParticipants receiving PrEP through Blued+193 Participants
Blued AppFeasibility of Blued+ in ChinaParticipants receiving HIV testing through Blued+316 Participants
Primary

System Usability Scale (SUS)

Acceptability of Blued+ in China will be measured using the System Usability Scale (SUS). The SUS is a widely used scale that evaluates the usability of products and systems through a 10-item question set. The total range of a score on this scale is 0 to 100. This scale does not have any sub-scales. Higher scores on this scale represent higher levels of intervention usability, with 100 being the highest usability and 0 being the lowest usability. Information on this scale and how to calculate values is found in: Bangor, Aaron, Philip T. Kortum, and James T. Miller. An empirical evaluation of the system usability scale. Intl. Journal of Human-Computer Interaction 24.6 (2008): 574-594. The intervention will be considered acceptable if it reaches a total SUS rating score of ≥ 71/100, which has been interpreted as being 'good' usability.

Time frame: 12 months after intervention initiation, 15 months after first study interaction

Population: Participants completing all items in the SUS scale

ArmMeasureValue (MEAN)Dispersion
Blued AppSystem Usability Scale (SUS)73.4 score on a scaleStandard Deviation 14.4

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026